QURE News

uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors May Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages uniQure N.V. Investors to Secure Counsel Before Important Deadline in Securities Class Action - QURE

Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm

Class Action Announcement for uniQure N.V. Investors: A Securities Fraud Class Action Lawsuit Was Filed Against uniQure N.V.

Pomerantz LLP Advises of Securities Class Action Against uniQure N.V. – QURE

QURE SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that uniQure N.V. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Pomerantz LLP Advises Shareholders of Class Action Filing Against uniQure N.V. – QURE

ROSEN, A LEADING LAW FIRM, Encourages uniQure N.V. Investors to Secure Counsel Before Important Deadline in Securities Class Action - QURE

Pomerantz LLP Advises Investors of Class Action Involving uniQure N.V. – QURE

QURE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that uniQure N.V. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!